Samsung Bioepis highlights drug access, innovation efforts

[Courtesy of Samsung Bioepis]

Samsung Bioepis announced on Thursday that it published its 2024 Sustainability Management Report, which details its efforts and accomplishments in expanding drug access, driving research and development innovation, and enhancing product quality and patient safety.

The report includes financial as well as non-financial business achievements aimed at enhancing stakeholder value and stressed the company’s ongoing commitment to transparency and accountability. The company has released three sustainability reports since 2021.

In terms of drug access, Samsung Bioepis emphasized its role in providing high-quality biosimilar products at reasonable prices compared to their reference products, thereby helping to save medical costs, while in R&D, the company highlighted its ongoing efforts to expand its biosimilar pipeline, discover sustainable growth drivers, advance its development platform, and cultivate biotech specialists.

The company also underscored its commitment to improving product quality and patient safety via a comprehensive quality management system that oversees the entire lifecycle of its pharmaceuticals, aiming to prevent quality risks and ensure the highest safety standards.